先健科技(01302.HK):IBSAngel項目已經提交CEMARK註冊申請
格隆匯11月8日丨先健科技(01302.HK)公告,經獨立第三方專業諮詢機構評估建議,於2019年11月8日,先健深圳與合資公司簽訂了技術轉讓合同。
根據技術轉讓合同,先健深圳同意將IBSAngelTM鐵基可吸收肺血管支架系統 項目相關專利及IBSTitanTM鐵基可吸收外周支架系統 項目相關專利轉讓予合資公司。轉讓價款為人民幣1147萬元,該金額是由一間獨立合資格估值公司按公允價值評估得出。
截止公告日,IBSAngel項目已經提交CEMARK註冊申請,IBSTitan項目正在籌備啟動中國和歐洲的多中心臨牀研究。為支持上述業務的開展,先健深圳與合資公司訂立了該技術轉讓合同。此次安排進一步落實了集團發展合資公司的生物可吸收材料項目的業務以及擴展集團產品組合的計劃,集團將持續為合資公司的健康良好運營而助力,不斷提升集團綜合實力及競爭力。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.